EUVIMEDEUVIMED entdecken
Crossref

Secretory Carcinoma of Breast: A Population-Based Study

Ahmet Necati Sanli, Deniz Esin Tekcan Sanli, M Kadri Altundag, Fatih Aydogan

The American Surgeon™ · 2024

DOI: 10.1177/00031348231199174 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Surgeon™, 2024. Verfasst von Ahmet Necati Sanli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Abdulkadir Yuksel State Hospital, Gaziantep, Turkey. Hauptthemen laut MEDLINE: Breast Neoplasms, Carcinoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

In this study, it was aimed to evaluate the characteristic features and survival of secretory carcinoma of the breast (SCB), which is one of the rare malignant tumors of the breast.

Methods

Data of patients with histopathological diagnosis of SCB between 2010 and 2019 were extracted from the SEER database. These patients were evaluated in terms of age, race, molecular subtype, grade, estrogen receptor (ER), progesterone receptor (PR), HER2 receptor, TNM stage, surgical status, chemotherapy and radiotherapy treatment. Overall survival (OS) and breast cancer-specific survival (BCSS) of the whole population and subgroups [in terms of surgery procedure (mastectomy/breast-conserving surgery), and hormone receptor status (positive/negative)] were analyzed.

Results

70 patients were included in the study. The mean age was 57 years (range 2-82). 32.9% of the patients were diagnosed under the age of 50. 97.1% of the patients were female; 2.9% were male. The vast majority of patients were white race (81.4%). Although the rates of localization were higher in the upper outer quadrant (31.4%), centrally located tumors (18.5%) were also quite common. The most frequently detected molecular subtype was hormone positive/HER2 negative. All patients were non-metastatic, 81.4% of patients did not have lymph node metastases, and most of the patients were stage IA. Median follow-up was 37 months (range 0-118 months). Considering all patients, OS was 76.3%, 5-year OS was 91.8%, and BCSS was 88%, 5-year BCSS was 97.8%. There was no statistically significant difference in OS and BCSS according to subgroups ( P > .01).

Conclusion

SCB, a rare histopathologic type, has high OS and BCSS rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCarcinomaHumansFemaleMaleChild, PreschoolChildAdolescentYoung AdultAdultMiddle AgedAgedAged, 80 and overMastectomyHormonesSEER Program

Stichwörter der Autor:innen

breast cancer survivaljuvenile breast carcinomasecretory breast carcinomasurveillance, epidemiology, and end results

Substanzen

Hormones

Autor:innen und Institutionen

  • Department of General Surgery, Abdulkadir Yuksel State Hospital, Gaziantep, Turkey.
  • Department of Radiology, Faculty of Medicine, Gaziantep University, Gaziantep, Turkey.
  • MKA Breast Cancer Clinic, Ankara, Turkey.
  • Breast Health Center, Memorial Bahcelievler Hospital, Istanbul, Turkey.
  • Department of General Surgery, Faculty of Medicine, Kirklareli University, Kirklareli, Turkey.

Zitieren

APA

Sanli, A. N., Tekcan Sanli, D. E., Altundag, M. K., & Aydogan, F. (2024). Secretory Carcinoma of Breast: A Population-Based Study. The American Surgeon™. https://doi.org/10.1177/00031348231199174

Vancouver

Sanli AN, Tekcan Sanli DE, Altundag MK, Aydogan F. Secretory Carcinoma of Breast: A Population-Based Study. The American Surgeon™. 2024. doi:10.1177/00031348231199174

BibTeX
@article{Sanli2024,
  author = {Sanli, Ahmet Necati and Tekcan Sanli, Deniz Esin and Altundag, M Kadri and Aydogan, Fatih},
  title = {Secretory Carcinoma of Breast: A Population-Based Study},
  journal = {The American Surgeon™},
  year = {2024},
  doi = {10.1177/00031348231199174}
}
Kostenlos starten →